The Enterprise Value as of December 2024 (TTM) for Y-mAbs Therapeutics, Inc. (YMAB) is 297.98M

According to Y-mAbs Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 297.98M. This represents a change of -34.46% compared to the average of 454.65M of the last 4 quarters.

Y-mAbs Therapeutics, Inc. (YMAB) Historical Enterprise Value (quarterly & annually)

How has YMAB Enterprise Value performed in the past?

The mean historical Enterprise Value of Y-mAbs Therapeutics, Inc. over the last ten years is 693.76M. The current 297.98M Enterprise Value has changed 4.20% with respect to the historical average. Over the past ten years (40 quarters), YMAB's Enterprise Value was at its highest in in the December 2020 quarter at 1.96B. The Enterprise Value was at its lowest in in the June 2017 quarter at 0.

Y-mAbs Therapeutics, Inc. (YMAB) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Y-mAbs Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Y-mAbs Therapeutics, Inc. (YMAB) Average Enterprise Value

How has YMAB Enterprise Value performed in the past?

The current Enterprise Value of Y-mAbs Therapeutics, Inc. (YMAB) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Y-mAbs Therapeutics, Inc. (YMAB) Enterprise Value vs. Peers

How is YMAB’s Enterprise Value compared to its peers?

Y-mAbs Therapeutics, Inc.’s Enterprise Value is greater than TCR2 Therapeutics Inc. (79.12M), less than Revolution Medicines, Inc. (7.98B), greater than Black Diamond Therapeutics, Inc. (123.50M), greater than Atreca, Inc. (-8620212.00), greater than Passage Bio, Inc. (33.76M), less than bluebird bio, Inc. (373.49M), greater than Mersana Therapeutics, Inc. (152.76M), greater than Zentalis Pharmaceuticals, Inc. (228.61M), less than Travere Therapeutics, Inc. (1.86B), greater than Generation Bio Co. (143.59M), greater than Kronos Bio, Inc. (8.15M), less than Erasca, Inc. (710.66M), greater than C4 Therapeutics, Inc. (280.63M), less than Edgewise Therapeutics, Inc. (2.76B), less than Arcutis Biotherapeutics, Inc. (1.83B), less than Icosavax, Inc. (713.87M), less than Mirum Pharmaceuticals, Inc. (2.12B), less than VectivBio Holding AG (848.58M), less than Day One Biopharmaceuticals, Inc. (857.57M), less than Vaxcyte, Inc. (9.69B), greater than Larimar Therapeutics, Inc. (211.48M), less than Syndax Pharmaceuticals, Inc. (983.46M), less than Merus N.V. (2.47B), greater than Sutro Biopharma, Inc. (9.43M),

Build a custom stock screener for Y-mAbs Therapeutics, Inc. (YMAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Y-mAbs Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Y-mAbs Therapeutics, Inc. (YMAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Y-mAbs Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.